THE HACKS WE CAN'T SEE: What Can a Hacker Do with Your Genetic Information?
By Kaleigh Rogers,
VICE Motherboard
| 07. 26. 2016
Learning about the genetic markers stored in your DNA can be an illuminating experience, even a life-altering one. Now that direct-to-consumer genetic testing companies such as 23andMe have made these tests more accessible and affordable, it’s no wonder that more than 1 million people have shipped their spit off to be genotyped, and have all their genetic information catalogued (and sold) in the process.
When a massive cache of private information is all stored in one place, it will naturally be a target for hackers. Though there hasn’t been a hack of any consumer genetic testing company yet, it may just a matter of time before someone breaches one of these sites and gains access to not just your credit card, but also your genetic markers.
So how concerned should we be, and what might happen if a hacker ever did get his or her hands on your DNA?
“You can imagine scenarios where unsavory people could try to use this stuff in personal ways,” said Dr. Robert Green, the director of the Genomes to People research...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...